Charcot-Marie-Tooth disease type 2A (CMT2A) is an autosomal dominant axonal form of peripheral neuropathy caused by mutations in the mitofusin 2 gene (MFN2), which encodes a mitochondrial outer membrane protein that promotes mitochondrial fusion. Emerging evidence also points to a role of MFN2 in the regulation of mitochondrial metabolism. To examine whether mitochondrial dysfunction is a feature of CMT2A, we used a transgenic mouse model expressing in neurons a mutated R94Q form of human MFN2 shown to induce a CMT2A phenotype. Oxygraphic and enzymatic measurements both revealed a combined defect of mitochondrial complexes II and V (40 and 30% decrease, respectively) in the brain of Tg-R94 mice, leading to a drastic decrease of ATP synthesis. These deficiencies were reversed by the mitochondrial ATP-sensitive potassium channel (mK ATP ) inhibitor 5-hydroxydecanoate. Conversely, in controls and wild-type human MFN2 mice, the mK ATP activator diazoxide mimicked the deficiency observed with the R94Q mutation. The physical links between complexes II and V, previously proposed as part of mK ATP , were reinforced in Tg-R94Q mice. Our results show that the R94Q MFN2 mutation induces a combined defect of complexes II and V linked to the opening of mK ATP , which could participate in the pathophysiology of the disease.
Charcot-Marie-Tooth disease (CMT) consists of a group of inherited peripheral motor and sensory neuropathies (1), generally characterized by progressive muscular atrophy and weakness with sensory loss in the distal extremities of the limbs. CMT2A (MIM 609260), the most common axonal form of the disease, is mainly caused by mutations in the MFN2 gene (2) . This gene encodes the dynamin GTPase mitofusin 2 (MFN2) located in the outer mitochondrial membrane (3, 4) .
Mitochondria are highly dynamic organelles that undergo continuous cycles of fission and fusion. Together with MFN1 and the optic atrophy 1 protein (OPA1), MFN2 plays a major role in the mitochondrial fusion process in mammalian cells (3) (4) (5) .
Due to the polarity of neurons, with long axons and dendrites, high energy levels are often required far from the soma. Mitochondrial transport and distribution patterns are thus particularly crucial for neurons. Abnormal accumulations of mitochondria have been observed in the distal axon of sural nerve biopsies of patients with CMT2A (6, 7) , and mitochondrial aggregations around the nucleus have also been found in mouse embryonic fibroblasts and dorsal root ganglion neurons expressing some CMT2A disease mutations (8, 9) . Mitochondrial morphology was not affected in fibroblasts of CMT2A patients carrying a MFN2 mutation (10, 11) ; however, these mitochondria demonstrated a decrease in efficiency of oxidative phosphorylation (OXPHOS) and in membrane potential (⌬⌿ m ; ref. 10 ). Moreover, down-regulation of MFN2 in L6E9 myotubes has been shown to induce a reduction in glucose oxidation and ⌬⌿ m (12, 13) . These mitochondrial defects provide additional evidence of the role of MFN2 in cell bioenergetics (14) .
Recently, a transgenic mouse model of CMT2A has been generated by expressing in neurons a human cDNA carrying the MFN2 p.R94Q mutation (Tg-R94Q; ref. 15 ). This particular missense mutation, located immediately upstream of the GTPase domain of MFN2, has been reported in 7 unrelated patients affected by CMT2A (2, 6, 16, 17) . Tg-R94Q mice show the main clinical symptoms encountered in patients with CMT2A, namely locomotor impairment and grip-strength defect, whereas no abnormalities were observed in transgenic mice expressing the wild-type human MFN2 (Tg-WT). Tg-R94Q mice also presented an axonal atrophy in the distal sciatic nerve preferentially affecting myelinated axons Ͼ3.5 m in diameter, thereby increasing the proportion of smaller axons. Interestingly, the number of mitochondria per axon was significantly higher in the distal part of these axons than in the larger axons.
In Tg-R94Q mouse embryonic fibroblasts, mitochondrial fusion is maintained by the interaction of MFN2 p.R94Q with MFN1 (8) . To address the question of a bioenergetic impairment in the pathogenesis of CMT2A, we compared oxidative phosphorylation and respiratory chain activity in isolated mitochondria from the brain tissue of Tg-R94Q mice with that in Tg-WT and control mice.
MATERIALS AND METHODS

Animals
The human MFN2 mutation p.R94Q was expressed in the nervous tissue of C57BL6 mice to constitute a CMT2A transgenic mouse model having a motor defect. The R94 residue is located immediately upstream of the GTPase domain of MFN2. Human and mouse MFN2 are 95% identical, and all the residues that were found mutated in the original CMT2A study, including p.R94Q (2) , are conserved in mouse MFN2 (8) . C57BL6 mice, with the human MFN2 transgene (Tg-Wt: mitoCharc0; ref. 15) or with the mutated human MFN2 p.R94Q transgene (Tg-R94Q: mitoCharc1; ref. 15 ) were used; all were obtained from the Department of Cell Biology, University of Geneva. C57BL6 and Tg-Wt mice were used as controls to specifically study the effect of the p.R94Q mutation. Transgenic mice were generated by oocyte injection of human MFN2 cDNA carrying the p.R94Q mutation. Transgene expression was targeted to differentiated neurons by the neuron-specific enolase promoter. Transgenic animals were identified by PCR analysis, and transgene expression was confirmed by real-time quantitative RT-PCR in the principal cerebral tissues (15) . The expression levels of human MFN2 transgenes in the cortex represented 1/5 of mouse MFN2 endogenous expression, i.e., in both Tg-Wt and Tg-R94Q mice the MFN2 expression level (endogenous and exogenous) was 1.2 times that of MFN2 in control mice (not shown).
Mitochondrial isolation from mouse brain tissue
Mice (age 7 to 9 mo) were anesthetized with isoflurane, in accordance with European Community Guidelines (directive 86/609/CEE), before decapitation and dissection of the cerebral cortex. The isoflurane volume inhaled was strongly controlled and identical for each animal; moreover, preliminary experiments made without the anesthetic showed that the isoflurane volume used had no effect on the mitochondrial parameters investigated, even in Tg-R94Q mice.
The cerebral cortex was diced in 1 ml isolation buffer I/100 mg brain (250 mM sucrose, 10 mM Tris-HCl, 1 mM EDTA, and 0.25 mg/ml fatty acid-free BSA, pH 7.4) before homogenization with 11 up-and-down strokes in a 50-ml potter and 3 up-and-down strokes in a 10-ml tight-fit potter at 1000 rpm. Cell debris were pelleted at 3200 g for 10 min, and the supernatant was collected, filtered through gauze, and centrifuged at 10,000 g for 10 min. The mitochondrial pellet was washed with buffer I and centrifuged at 6500 g for 10 min before resuspension in 0.3 ml of buffer R (250 mM sucrose, 2 mM EDTA, and 20 mM Tris-base, pH 7.4) and conserved on ice. The entire operation was performed at 4°C and completed in Ͻ1 h.
Mitochondrial respiratory rates
Brain mitochondria were resuspended in respiratory buffer (225 mM sucrose, 10 mM Tris-HCl, 5 mM KH 2 PO 4 , 10 mM KCl, 1 mM EDTA, 4 mM MgCl 2 , and 0.1 mg/ml fatty acid-free BSA, pH7.4). Mitochondrial oxygen consumption was measured at 37°C using a 2-channel, high-resolution Oxygraph respirometer (Oroboros, Innsbruck, Austria). Resting respiration (state 2) was initiated in the presence of either complex I substrate (5 mM malate and 2.5 mM pyruvate) or complex II substrate (5 mM succinate supplemented with 10 M rotenone), and then maximal ADP-stimulated respiration (state 3) was measured with one addition of saturating ADP concentration (0.5 mM). Cytochrome c was added (8 M) to check outer mitochondrial membrane integrity. Finally, in one oxygraphic chamber, 2 g/ml oligomycin was added (state 4), and the capacity of the electron transport system was recorded by uncoupling respiratory chain using 1 M carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP). The respiratory control ratio (RCR), defined as state 3/state 4, was used to evaluate the coupling of respiration to phosphorylation. In the second chamber, antimycin was added, and COX-linked respiration was analyzed using 50 mM ascorbate and 5 mM N,N,N Ј ,N Ј -tetramethyl-p-phenylenediamine as substrates. The effects of diazoxide (DZX) and 5-hydroxydecanoate (5HD) on succinate-driven respiration was analyzed on brain mitochondria (0.05 mg/ml) resuspended in the respiratory buffer and incubated within the chambers of the oxygraph with 100 M DZX and/or 500 M 5HD during 10 min.
The ATP synthesized in situ was measured as described previously by Cairns et al. (18) . Aliquots were sampled at 30-s intervals, quenched with an equal volume of 7% perchloric acid, and preserved at Ϫ80°C. The ATP content was measured from neutralized supernatants by an assay based on a tandem enzyme reaction driven by hexokinase (0.9 U/ml) and glucose-6-phosphate dehydrogenase (0.1 U/ml), which, in the presence of ATP and glucose (1 mM), converts NADP (0.5 mM) to NADPH at an equimolar ratio.
Mitochondrial enzymatic activities
The activities of the mitochondrial OXPHOS complexes (I-IV) and of the Krebs cycle enzymes in brain mitochondria were measured at 37°C on a Beckman DU-640B spectrophotometer (Beckman Coulter, Brea, CA, USA) using an adaptation of the method described by Rustin et al. (19) . Complex V (ATP synthase) activity was measured by a coupled assay (19) using lactate dehydrogenase and pyruvate kinase as the coupling enzymes on sonicated mitochondria (6ϫ5 s, MSE sonicator). For the study of the mitochondrial ATP-sensitive potassium channel (mK ATP ) modulators, the activity was measured without FCCP to avoid IF1 binding through the loss of mitochondrial membrane potential. Complex II (succinate ubiquinone reductase) activity was measured in a reaction medium containing 50 mM phosphate buffer (pH 7.5), 2.5 mg/ml fatty acid-free BSA, 1 mM KCN, 5 M rotenone, 5 g/ml antimycin, 30 mM succinate, 0.1 mM 2,6-dichlorophenolindophenol (DCPIP), and 5 g of mitochondrial proteins. After 2 min of incubation at 37°C, the reaction was initiated by addition of 0.05 mM decylubiquinone. The activity was measured at 600 nm by monitoring the reduction of DCPIP. Succinate dehydrogenase (SDH) activity was measured after the reduction of DCPIP in the presence of 1 mM phenazine methosulfate and 15 mM succinate at 600 nm (20) . Specific activities were controlled using thenoyl trifluoroacetate, a succinate ubiquinone reductase inhibitor.
Protein expression
Western blotting was performed on 20 g of brain mitochondrial proteins solubilized in a Laemmli buffer and boiled for 5 min. at 50°C. Proteins were separated on a 12.5% SDSpolyacrylamide gel and electroblotted to PVDF membranes (Amersham Biosciences, Les Ulis, France). Mouse monoclonal VDAC, complex V subunit ␣ (55 kDa) and ␤ (56 kDa) antibodies, and complex II subunit SDHA (70 kDa) and SDHB (30 kDa) antibodies were used for complex subunit detection (Mitosciences, Eugene, OR, USA).
Coimmunoprecipitation (CoIP) experiment
IP was performed on mitochondria from 2 mice from the same groups pooled together. As recommended by the immunocapture kit supplier (Mitosciences), 0.6 mg mitochondria diluted in PBS was solubilized by addition of 1% (w/v; 2.5 g/g mitochondrial protein) digitonin. Complex extraction and integrity were controlled by blue native-PAGE (21) on 3-12% polyacrylamide gels (Invitrogen, Carlsbad, CA, USA), and IP input was also controlled by SDS-PAGE (see above). Samples were then incubated overnight under wheel rotation at 4°C with anti-native complex I, II, or V monoclonal antibody (mAb) covalently linked to G-agarose beads (MS 101, 201, and 501c; Mitosciences) in a ratio of 60 g Abs/mg mitochondria. Beads were then washed 3 times in either 1 mM dodecyl-maltoside (DDM) or digitonin dissolved in PBS, and elution was performed in a solution of 200 mM glycine and 1 mM DDM (pH 2.5). After neutralization, collected fractions were submitted to SDS-PAGE and electroblotted to PVDF membranes. mAbs against complex II SDHA and SDHB subunits, complex V␣ and V␤ subunits, and complex I (NDUFB8), III (IIIcore2), and IV (COX1) subunits were all supplied by Mitosciences and used according to the manufacturer's recommendations. Manufacturer-supplied brain mitochondria were used as control for mAb specificity.
mK ATP channel activity
Modulation of mK ATP channel activity by openers (DZX) and inhibitors (5HD) was monitored spectrophotometrically (DU-640B spectrophotometer) at 520 nm, as the light-scatter (absorbance) change due to K ϩ uptake, as described elsewhere (22) . Respiring mitochondria take up K ϩ and osmotically obligated water when suspended in K ϩ medium, leading to matrix swelling. An increase in matrix volume is accompanied by a decrease in absorbance at 520 nm; which is an isosbestic point for the mitochondrial cytochromes and is therefore insensitive to changes in redox state. The mK ATP K ϩ buffer (100 mM KCl, 5 mM HEPES, 10 mM succinate, 10 M rotenone, 2 g/ml oligomycin, 100 M EGTA, 5 mM MgCl 2 , 2 mM KH 2 PO 4 , and 0.1 mg/ml BSA, pH 7.2 at 37°C) was rapidly added to a cuvette containing 0.5 mg/ml mitochondria. The change in optical density at 520 nm was recorded for 30 s, and the swelling, reflecting the increase in mK ATP opening, was calculated as ␤, which is the inverse ⌬ absorbance (1/⌬ A ) normalized for protein concentration (23) . Mitochondrial incubation in the K ϩ medium induced a maximal swelling ("100%" swelling), and the new steady state of potassium influx/efflux measured after addition of inhibitors and activators is thus reported to this value (23) . For control experiments (nonspecific salt transport), KCl was replaced with NaCl in the buffer. The swelling was measured immediately after the mitochondria were isolated, i.e., in Ͻ1 h after brain dissection.
Statistical analysis
Statistical comparisons between control, Tg-Wt, and Tg-R94Q mice were made with the Mann-Whitney U test. The Wilcoxon test for paired data was used for the analysis of the effects of drugs on mitochondria. Differences were considered statistically significant at values of P Ͻ 0.05.
RESULTS
Mitochondrial complex II and V deficiencies in the brain mitochondria of Tg-R94Q mice
First, maximal coupled respiration, RCR, and ATP synthesis were analyzed in brain mitochondria from control, Tg-Wt, and Tg-R94Q mice (Fig. 1A) . ADPstimulated (state 3) respiration driven by complex I substrates (malate and pyruvate) did not differ between Tg-R94Q, Tg-Wt, and control mice (Fig. 1A1) . However, the addition of saturating ADP concentration failed to stimulate complex II-linked respiration in mitochondria from Tg-R94Q mice, as shown by the decrease of both the state 3 succinate-driven respiration and the RCR, i.e., the ratio of oxygen consumption in the presence of ADP to that in its absence (Fig. 1A1, 2) . In accordance with the respiratory measurements, the rate of succinate-driven ATP synthesis was reduced by nearly 80% (Fig. 1A3 ) in mitochondria from Tg-R94Q mice compared with Tg-Wt and control mice, whereas no difference was found with malate and pyruvate.
The specificity of complex II-linked respiration inhibition was further analyzed using substrates of the different complexes, alone or in combination (Fig.  1B2 ). As described above, in the presence of malate and pyruvate, ADP did stimulate respiration over state 2 (no adenylate), even in Tg-R94Q mitochondria. In control and Tg-Wt mitochondria, complex I-linked (Fig. 1B2 , MP) and complex II-linked (Fig. 1B2, SR) respiration showed comparable maximal rates, while convergent electron flow from both complexes (Fig. 1B2, MPS) further increased coupled respiration. In Tg-R94Q mitochondria, succinate failed to stimulate respiration over malate/pyruvate but rather tended to limit the respiration rate (Fig. 1B2, MPS) . The respiration rate further dropped following rotenone addition (complex II-linked respiration; Fig. 1B2, SR) . Thus, when succinate is oxidized, both states 3 (Fig. 1B2 , MPS and SR) were lower in Tg-R94Q mitochondria than in control and Tg-Wt. Glycerol-3-phosphate (G3P) dehydrogenase and complex II both supply electrons provided by FADH 2 oxidation to ubiquinone and complex III. After inhibition of succinate oxidation by malonate (Fig. 1B2,  ϩmalo) , no difference was noted between the groups using G3P as substrate. Lastly, cytochrome c oxydaselinked respiration did not differ either (not shown). Taken together, these data point to a specific succinate oxidation defect.
However, while ADP failed to stimulate the succinatedriven respiration in Tg-R94Q mice, uncoupling by FCCP partially reversed this inhibition (Fig. 1B1) , suggesting that the inhibition of succinate oxidation was partially reversed when bypassing the complex V.
To further investigate this succinate oxidation defect, succinate-driven respiration was gradually stimulated by small additions of either FCCP (no adenylate added) or ADP. The FCCP titration gradually stimulates respiration by increasing proton permeability without involving the phosphorylation machinery, whereas ADP titration stimulates H ϩ reentry by gradual activation of the complex V. For each value of ADP or FCCP, succinate respiration was lower in mitochondria from Tg-R94Q mice than in controls (Fig. 1C, top panel) , pointing once again to a limitation involving complex II. However, above a threshold value, ADP failed to stimulate respiration to the level obtained with FCCP in Tg-R94Q mitochondria, while it did so in control and Tg-Wt mitochondria (Fig. 1C, top panel) . Thus, the apparent affinity for ADP, calculated from the Lineweaver-Burk transformations, decreased 7-fold for values Ͼ0.025 mM ADP in Tg-R94Q mice (apparent K m ADP 21.8Ϯ15.6 to 154.4Ϯ41.1 M in Tg-R94Q; Supplemental Fig. S1 ).
Two explanations may be proposed for this difference: an inhibitory effect of ADP on respiration or a difference due to the phosphorylation machinery [F0F1-ATP synthase, P i carrier (PiC), or ATP/ADP translocase (ANT)]. To rule out a possible inhibition of succinate oxidation by ADP, titration of succinate- linked respiration with FCCP in state 3 was performed (Fig. 1C, bottom panel) . In Tg-R94Q mitochondria, FCCP alone, or in combination with ADP, gave the same respiratory rates and always stimulated respiration to a higher rate than did ADP alone in Tg-R94Q mitochondria. This supports the hypothesis of a limitation of proton permeation at the level of the phosphorylation machinery.
Enzymatic activities of the OXPHOS complexes were then assessed in mitochondria from Tg-R94Q, Tg-Wt, and control mice ( Table 1) . No difference was found in the activities of complexes I, III, and IV. However, SDH and succinate ubiquinone reductase (SUR) activities carried out by complex II decreased by 40 and 20%, respectively (PϽ0.001) in mitochondria from Tg-R94Q mice compared with Tg-Wt and control mice. Complex V activity also decreased (30%; PϽ0.01) in Tg-R94Q compared with control mice, while it increased (PϽ0.05) in Tg-Wt compared with control mice. No difference was found in the quantity of the catalytic subunits of the 2 complexes, i.e., the SDHA and SDHB subunits of complex II, and the ␣ and ␤ subunits of complex V (Supplemental Fig. S2 and Fig. 2) .
SDH structurally interacts with complex V
The coexisting defect of complexes II and V observed in Tg-R94Q mice led us to analyze the possibility of a physical interaction between SDH and complex V using CoIP experiments. Mitochondria were digitonin solubilized (control inputs; Fig. 2A, B) and immunoprecipitated with anti-native F 1 -ATPsynthase mAb (Fig. 2C) , anti-native complex II mAb (Fig. 2D) , or anti-native complex I (Fig. 2E) . IP was followed by SDS-PAGE and immunoblotting using anti-complex II (SDHA and SDHB subunits) and anti-complex V (V␤ and V␣ subunits). Both mitochondrial SDHA (the 70-kDa flavoprotein) and SDHB (the 30-kDa iron-sulfur subunit) coimmunoprecipitated with complex V (Fig. 2C) ; inversely, both subunits V␤ and V␣ coimmunoprecipitated with complex II (Fig. 2D, V␣ not shown) . Neither SDH nor Enzymatic activities of OXPHOS complexes measured in mitochondria isolated from the brain tissue of Tg-Wt, Tg-R94Q, and control mice. Values represent mean Ϯ se activity (nmol/min/mg protein) normalized to citrate synthase (CS). *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001 vs. control; # P Ͻ 0.05, ## P Ͻ 0.01 vs. Tg-Wt. V␤/V␣ bands were detected after complex I immunoprecipitation (Fig. 2E) . Moreover, no band was detected in complex II or V CoIP experiments using anti-complex I (subunits NDUFB8, 20 kDa), anticomplex IV (COX 1, 39 kDa; Fig. 2C, right panel) , or anti-complex III (subunit core2, not shown) antibodies. Interestingly, the intensity of SDHA and, more strikingly, SDHB bands was significantly greater in complex V IP extracts of Tg-R94Q mice compared with control and Tg-Wt mice. A higher proportion of V␤ subunits also coimmunoprecipitated with complex II in Tg-R94Q mitochondria. These results suggested either a stronger interaction between complex V and SDH proteins or a larger quantity of interacting complexes.
Complex II and V deficiencies are linked to the opening of mK ATP channels
SDH has been shown to interact with complex V, ANT, PiC, and ATP-binding cassette protein 1 (ABC1) in a macromolecular supercomplex designated as the mK ATP (24) . Moreover, the opening of mK ATP channels by DZX decreased succinate oxidation and reduced activity of complexes II and V (25) (26) (27) (28) (29) (30) . In Tg-R94Q mice, the functional state of mK ATP channels was analyzed by the light-scatterring assay using mK ATP channel modulators. A KCl buffer was used to induce maximal mitochondrial swelling as a control condition (Fig. 3) . ATP, a known mK ATP channel inhibitor, prevented this mitochondrial swelling in control, TgWt, and Tg-R94Q mice (Fig. 3, top and middle panels) . In Tg-Wt and control mice, the reopening of mK ATP channels by DZX and the inhibition of SDH by malonate counteracted the effect of ATP, leading to mitochondrial swelling, while 5HD, an mK ATP channel inhibitor, reversed the effects of DZX and malonate. In Tg-R94Q mice (Fig. 3, bottom panel) , DZX and malonate failed to stimulate swelling over the level observed with ATP. Consequently, 5HD ϩ DZX did not differ from DZX treatment in the case of Tg-R94Q mice. Surprisingly, the combination of 5HD and malonate allowed mitochondrial swelling.
As described above (Table 1) , complex II (SDH) and complex V activities decreased in mitochondria from Tg-R94Q mice compared with control mice. We secondly studied the effect of mK ATP channel modulators on the enzymatic activities of SDH and ATP synthase (Fig. 4A, B) . It should be noted that chemicals were first added to intact mitochondria and allowed to act for 10 min before the mitochondria were frozen. DZX decreased SDH activity of mitochondria from Tg-Wt and control mice to that of Tg-R94Q mice, as did malonate (Fig. 4A) . The effect of DZX on the SDH activity of mitochondria from Tg-Wt and control mice was reversed by 5HD. In Tg-R94Q mitochondria, malonate and DZX could not decrease SDH activity any further, while 5HD on its own increased SDH activity to the level of mitochondria from Tg-Wt and control mice. DZX also decreased complex V activity in Tg-Wt and control mitochondria (Fig. 4B) . Moreover, 5HD on its own had no effect on complex V activity in Tg-Wt and control mitochondria but restored Tg-R94Q complex V activity to the level observed in Tg-Wt and control mitochondria. In the presence of DZX, 5HD only partially increased the complex V activity in Tg-Wt and control mitochondria.
Contrary to the direct action of SDH inhibitors such as malonate, the inhibition of SDH by DZX disappeared after mitochondrial membrane disruption (freezing and thawing); the complex V inhibition by DZX was limited as well. The effect of 5HD on Tg-R94Q mitochondria also disappeared in these conditions (Supplemental Fig. S3) .
Finally, the relation between succinate oxidation and mK ATP channel opening was studied by polarography (Fig. 4C) . As reported above, state 3 succinate respira- Figure 3 . mK ATP channel swelling/light-scatter assay in mitochondria from brain tissue of control, TgWt, and Tg-R94Q mice. Magnitude of mK ATP channel swelling, normalized to control K ϩ condition, as determined by a decrease in absorbance after 0.3 min incubation in K ϩ medium. When indicated, 1 mM ATP, and/or 100 M DZX, 500 M 5HD, or 100 M malonate were present in the medium. Results are expressed as means Ϯ se (controls and Tg-WT, nϭ5; Tg-R94Q, nϭ3). *P Ͻ 0.05, t *P Ͻ 0.1 vs. control; ¤ P Ͻ 0.05, t¤ P Ͻ 0.1 vs. ATP; ϩ P Ͻ 0.05, tϩ P Ͻ 0.1 vs. DZX or malonate.
tion was greatly decreased in Tg-R94Q mitochondria compared with Tg-Wt and control mitochondria. In Tg-Wt and control mitochondria, DZX decreased specifically the state 3 succinate-related respiration to the level observed in Tg-R94Q mitochondria. Consequently, the RCR with succinate as substrate did not differ any longer between mitochondria from Tg-Wt or control mice after the addition of DZX (1.18Ϯ0.10 and 1.47Ϯ0.34, respectively) and Tg-R94Q mice (1.51Ϯ0.76). 5HD fully restored ADPstimulated succinate oxidation in Tg-R94Q mitochondria. However, as for complex V activity, the decrease in succinate oxidation caused by DZX in Tg-Wt and control mitochondria was only partially restored. The respiratory rates were higher with DZX ϩ 5HD than with DZX alone in Tg-Wt and control mitochondria but did not attain normal respiratory values.
DISCUSSION
MFN2 plays a central role in mitochondrial outermembrane fusion and in the regulation of mitochondrial energetic metabolism. Metabolic explorations of cell models carrying MFN2 mutations responsible for CMT2A disease argue in favor of an energetic defect participating in the pathogenesis of the disorder (10, 12, 13) . We investigated mitochondrial energetic metabolism in a recently developed transgenic mouse model carrying the p.R94Q mutation, one of the most frequent human MFN2 mutations, which reproduces the peripheral neuropathy (15) . Our results show for the first time that an MFN2 mutation leads to a bioenergetic impairment in brain. None of the defects were observed in the transgenic mouse expressing the human nonmutated MFN2 cDNA, which excludes any effect linked to the slight MFN2 overexpression (15) . In Tg-R94Q mice, both SDH and SUR were decreased (40 and 20%, respectively). This complex II deficiency was combined with a complex V deficiency (30% decrease), which in turn greatly reduced succinate-related ATP synthesis. Impaired complex II and V activities were not linked to modifications of complex V assembly or content.
Interestingly, the succinate oxidation decrease in brain mitochondria from Tg-R94Q mice was revealed by the activation of complex V, since it was essentially observed during maximal coupled respiration (phosphorylation). Indeed, above an ADP threshold concentration of ϳ0.025 mM, the affinity of succinate-supported respiration for ADP was strongly reduced. This defect could be partially reversed when bypassing complex V. Indeed, the uncoupler FCCP, alone or in combination with ADP, stimulated succinate-driven respiration over state 3 in mitochondria from Tg-R94Q mice, while ADP, FCCP, or both gave the same respiration rates in mitochondria from Tg-Wt or control mice. This points to the phosphorylation machinery as a limiting step and is consistent with an involvement of complex V. More strikingly, impaired phosphorylation of ADP is only observed when complex II substrate, i.e., succinate, is oxidized. This inhibition could not rely on a direct inhibition of respiration by succinate, since the presence of this substrate did not reduce respiration when the SDH inhibitor malonate is also added (Fig.  1B2, see state 3 G3P condition) . Altogether, the functional analyses pointed to a succinate oxidation defect in brain Tg-R94Q mitochondria, revealed by the complex V activation or, inversely, an inactivation of the phosphorylation machinery by succinate oxidation. Due to the decrease in both complex V activity and ATP synthesis, which suggests a limitation of phosphorylation by ATP synthase, we focused our study on this complex. However, ANT and PiC also play an important role in phosphorylation regulation by supplying substrates (ADP and P i ) for ATP synthesis. ANT and PiC have been shown to form, with ATP synthase, the ATP synthasome responsible for the terminal step of ATP synthesis in mitochondria (25) . Thus, we cannot rule out the possibility that these two carriers also participate in the limitation of phosphorylation in Tg-R94Q mitochondria. A, B) SDH complex II (A) and complex V (B) mitochondrial enzymatic activities measured in brain mitochondria from control, Tg-Wt, and Tg-R94Q mice after incubation with 100 M DZX, 500 M 5HD, or 100 M malonate as indicated. Activities were normalized to citrate synthase (CS; nϭ5). C) State 3 oxygen consumption with complex II-dependent substrates, measured in mitochondria isolated from brain tissue of control, Tg-Wt, and Tg-R94Q mice in control conditions (DMSO treatment); in the presence of 100 M DZX (nϭ5); and, in the last condition, in the presence of DZX ϩ 500 M 5HD (controls and Tg-Wt; nϭ5) or 5HD only (Tg-R94Q, nϭ3) . Results are expressed as means Ϯ se (nmol/min/mg protein). *P Ͻ 0.05, t *P Ͻ 0.1 vs. control;
Although combined SDH and complex V deficiencies have been reported in humans (26) , there have been very few reports to date in the literature concerning a possible interaction between SDH and ATP synthase/ATP synthasome. Interestingly, SDH has been shown to associate with complex V, ANT, PiC, and ABC1 to form a macromolecular complex displaying a K ϩ transport activity that is sensitive to known mK ATP modulators (24) , and ANT has been shown to mediate the mK ATP -opener-induced potassium flux to the mitochondrial matrix (27) . Moreover, short repetitive ischemic episodes or the administration of DZX decreased succinate oxidation without affecting NADH oxidation in mitochondria isolated from rat and pig heart tissues (28 -31) . Decreased SDH activity has also been described, in these conditions, in the heart and cultured cortical neurons of rats (30, 32) . To sum up, ischemic and pharmacological preconditioning conditions linked to mK ATP channel activation mimic the impairment of the mitochondrial metabolism observed in Tg-R94Q mitochondria, i.e., the succinate oxidation defect and complex II and V inhibition. Conversely, all known SDH inhibitors, i.e., malonate, 3-nitropropionic acid, and atpenin A5, are shown to mediate protection from ischemia by the activation of mK ATP channels (32) (33) (34) . Complex V has also been described as a target for DZX (35, 36) , which favors complex V inhibition through the protein inhibitor of F1 (IF1; ref. 37). The hypothesis emerging from these studies is that the activities of complexes II and V, on the one hand, and mK ATP channel opening, on the other, are inversely related. A main reason would be that the same proteins are involved in both processes that would be mutually exclusive.
The results of the CoIP experiments performed on wild-type brain mitochondria extracts strongly suggest the existence of a physical association between complexes II and V, an association that would be reinforced in Tg-R94Q mitochondria. In mitochondria from these mice, the defects of complexes II and V were associated with an altered functional state of mK ATP channels. DZX, a specific mK ATP channel opener, and malonate, an SDH inhibitor, induced a K ϩ -dependent mitochondrial swelling in mitochondria from Tg-Wt and control mice but had no effect on mitochondria from Tg-R94Q mice. This could be linked to the lower enzymatic SDH activity that we found in mitochondria from Tg-R94Q mice. These results suggest that the mK ATP could not be further stimulated in these mitochondria, probably because the target by which DZX activates the mKATP opening is already occupied or activated. DZX, when added to Tg-Wt and control mitochondria, decreased the enzymatic activities of complexes II and V to the level of those in Tg-R94Q mitochondria (Fig. 5) . However, it did not affect these enzymatic activities in Tg-R94Q mitochondria. With DZX, the phosphorylating succinate-driven respiration was therefore inhibited at the same level as Tg-R94Q respiration.
Moreover, 5HD, the mK ATP inhibitor, fully reversed the effect of DZX on complex II activities in Tg-Wt and control mitochondria. This clearly links the action of DZX on SDH to the opening of mK ATP channels (Fig.  5) . However, 5HD only partially counteracted the effects of DZX on complex V activity and succinate oxidation in the presence of ADP. This suggested that one part of the DZX action on complex V activity is not specific to mK ATP channels. Interestingly, in Tg-R94Q mitochondria, 5HD fully restored succinate oxidation and the activities of complexes II and V.
To sum up, DZX, an mK ATP channel stimulator, mimicked the impaired biochemical phenotype observed in Tg-R94Q mitochondria, while 5HD, an mK ATP channel inhibitor, restored the impaired biochemical phenotype (Fig. 5) . These results argue in favor of higher rate/state of mK ATP channel opening in Tg-R94Q mitochondria. It is important to note that the effects of DZX and 5HD on SDH activity in Tg-R94Q and control mitochondria require the structural integrity of mitochondrial membranes, arguing for specific effects on an mK ATP macromolecular complex.
The results demonstrate a dominant negative effect of the R94Q Mfn2 mutation, leading to an mKATP opening and an OXPHOS defect, which is likely to participate to the pathophysiology of CMT2A. The mechanism linking mutated MFN2 to mK ATP opening and OXPHOS defect remains to be elucidated.
A direct interaction of MFN2 (outer mitochondrial membrane) with the respiratory chain and the mK ATP Figure 5 . Diagram representing the hypothesized effects of mK ATP channel modulators on mitochondrial SDH activity, complex V activity, and state 3 succinate-driven respiration. In Tg-R94Q mice, both complex II and V activities were impaired, which greatly reduced the coupled respiration linked to complex II substrate. In these mitochondria, the mK ATP channel inhibitor 5HD allows restoration of complex II and V activities and succinate oxidation. Inversely, in mitochondria from control mice, the mK ATP activator DZX induces a decrease in complex II and V activity and in succinate oxidation, mimicking the Tg-R94Q phenotype.
(inner mitochondrial membrane) is unlikely, since the large majority of MFN2 is exposed to the cytosol, and only a weak portion of the protein is located in the intermembrane space. However, although the energetic defect involves reactions taking place exclusively on the inner membrane, MFN2 has previously been shown to interact with a protein located in this membrane (38) . Moreover, some studies have reported that the intermembrane space loop of Fzo1, the MFN2 yeast ortholog, is an important domain for its interaction with the mitochondrial inner membrane (39, 40) .
The MFN2 mutation may also activate one of the mK ATP regulatory pathways, one of which is the calcium/IP3 pathway. Recently, a role of MFN2 protein in tethering endoplasmic reticulum mitochondria has been described (41) , and the silencing of MFN2 has been shown to disrupt efficient mitochondrial Ca 2ϩ uptake (41) . In addition, mK ATP activity is especially affected by changes in the volume of the mitochondrial matrix. An increase in mitochondrial density was observed in the distal axons of Tg-R94Q mice (15) and was attributed to an increase in the number of fission events leading to an increased number of organelles without affecting the total mitochondrial mass. Such variations of mitochondrial size could induce a contraction of the mitochondrial matrix, in turn activating the mK ATP channels.
In summary, this study constitutes the first demonstration of oxidative phosphorylation impairment in the neuronal cells of a CMT2A mouse model. The results also strongly argue in favor of functional links between complexes II and V within the mK ATP channel, links that are rarely evoked despite the abundant literature concerning the supercomplexes of the respiratory chain. Interestingly, mK ATP channels are particularly abundant in the brain, with 6 or 7 times more mK ATP channels than in other tissues (42) . This could partly explain the neurospecificity of CMT2A. These results reveal a new neuropathogenic mechanism underlying the energetic impairment related to the activation of mK ATP channels that could open new therapeutic perspectives.
